3399-22-2

Basic information

• Product Name: DIMETHYL TRANS-1,4-CYCLOHEXANEDICARBOXYLATE
• Synonyms: TRANS-1,4-DIMETHYL CYCLOHEXANEDICARBOXYLATE;4-Cyclohexanedicarboxylicacid,dimethylester,trans-1;dimethylester,trans-4-cyclohexanedicarboxylicacid;DIMETHYL TRANS-1,4-CYCLOHEXANEDICARBOXYLATE;DIMETHYL TRANS-CYCLOHEXANE-1,4-DICARBO-X YLATE;Dimethyl trans-1,4-cyclohexanedicarboxylate, 99+%;Dimethyl trans-1,4-Cyclohexanediarboxylate;(1r,4r)-dimethyl cyclohexane-1,4-dicarboxylate
• CAS NO: 3399-22-2
• Molecular Formula: C₁₀H₁₆O₄
• Molecular Weight: 200.23
• Product Categories: C10 to C11;Carbonyl Compounds;Esters;Building Blocks;C10 to C11;Carbonyl Compounds;Chemical Synthesis;Organic Building Blocks
• Mol File: 3399-22-2.mol

Chemical Properties

• Melting Point: 67-69 °C(lit.)
• Boiling Point: 263.5±0.0℃ (760 Torr)
• Flash Point: 115.4±18.8℃
• Appearance: White to faintly yellow/Crystalline Powder
• Density: 1.102±0.06 g/cm3 (20 ºC 760 Torr)
• Refractive Index: 1.4560 (589.3 nm 31℃)
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• BRN: 2213375
• CAS DataBase Reference: DIMETHYL TRANS-1,4-CYCLOHEXANEDICARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: DIMETHYL TRANS-1,4-CYCLOHEXANEDICARBOXYLATE(3399-22-2)
• EPA Substance Registry System: DIMETHYL TRANS-1,4-CYCLOHEXANEDICARBOXYLATE(3399-22-2)

Safety Data

• Hazard Codes: Xi
• Statements: 52/53-38
• Safety Statements: 22-24/25-61-37
• WGK Germany: 3
• TSCA: Yes
• Hazardous Substances Data: 3399-22-2(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 619-82-9 trans-hexahydroterephthalic acid 
• 79368-45-9 7-Oxobicyclo<2.2.1>heptan-1-carbonylchlorid 
• 149-73-5 trimethyl orthoformate 
• 94-60-0 dimethyl 1,4-cyclohexane dicarboxylate 
• 120-61-6 1,4-benzenedicarboxylic acid dimethyl ester 
• 64-19-7 acetic acid 
• 7647-01-0 hydrogenchloride 
• 186581-53-3 diazomethane 
• 15177-67-0 trans-4-(methoxycarbonyl)cyclohexanecarboxylic acid 
• 3919-11-7 trans-Cyclohex-2-ene-1,4-dicarboxylic acid 
• 1165952-91-9 cyclohexa-1,3-diene 
• 74-88-4 methyl iodide 
• 13170-66-6 trans-1,4-cyclohexanedicarboxylic acid dichloride 

Downstream Products

• 3236-48-4 trans-1,4-Cyclohexanedimethanol 
• 3236-47-3 (1s,4s)-cyclohexane-1,4-diyldimethanol 
• 619-82-9 trans-hexahydroterephthalic acid 
• 15177-67-0 trans-4-(methoxycarbonyl)cyclohexanecarboxylic acid 
• 15898-77-8 (Z)-1,4-bis(bromomethyl)cyclohexane 
• 1467-84-1 ((1R,4R)-4-aminocyclohexyl)methanol 
• 1256276-45-5 benzyl (trans-4-(hydroxymethyl)cyclohexyl)carbamate 

Relevant articles and documents

DEOXYNOJIRIMYCIN DERIVATIVES AS GLUCOSIDASE INHIBITORS

The present invention relates to novel iminosugars and their use as glucosidase inhibitors. The present inventors discovered that certain deoxynojirimycin derivatives may be effective in inhibiting glucosidases. In particular, such deoxynojirimycin derivatives may be useful for treating a disease or condition in which inhibition of glucosidase may play an important role.

Highly-efficient Ru/Al-SBA-15 catalysts with strong Lewis acid sites for the water-assisted hydrogenation of: P -phthalic acid

Ruthenium nanoparticles supported onto aluminum-doped mesoporous silica catalysts (Ru/Al-SBA-15) are fabricated using hydrothermal and impregnation methods for catalysis application. The Ru/Al-SBA-15-3 catalyst at a Si/Al molar ratio of 3 exhibited excellent catalytic performance for the hydrogenation of p-phthalic acid with high conversion efficiency (100.0%) and cis-isomer selectivity (84.0%) in water. Moreover, this system displays exceptional stability and recyclability through preserving the conversion efficiency, as well as a cis-isomer selectivity of 90.2 and 83.3%, respectively, after reusing it fourteen times. Such an exceptional system can also be ideal for the hydrogenation of aromatic dicarboxylic acids and their ester derivatives in water. Strong Lewis acid sites due to doped Al species play significant roles in the hydrogenation reaction. Moreover, isotope labeling studies indicated that water molecules effectively participated in the hydrogenation reaction. Hydrogen and water contributed half of the hydrogen atoms for this hydrogenation reaction. In the end, a plausible mechanistic pathway for the hydrogenation of p-phthalic acid using the Ru/Al-SBA-15-3 catalyst in water is proposed.

Preparation method of trans-1,4-cyclohexane dicarboxylic acid monomethyl ester

The invention discloses a preparation method of trans-1,4-cyclohexanedicarboxylic acid monomethyl ester. The preparation method comprises the following steps of using cis and trans mixed type dimethyl1,4-cyclohexanedicarboxylate with better solvent property in organic solvents as the raw material, performing isomerization reaction under the catalyzing action of an organic alkaline catalyst, and performing high-selectivity monoester hydrolyzing under the action of inorganic alkaline, so as to obtain the trans-1,4-cyclohexanedicarboxylic acid monomethyl ester. Compared with the prior art, the preparation method has the advantages that (1) the used raw material has good dissolvability in the organic solvent, such as methyl alcohol; (2) by adopting the optimized catalyst, the activating energy of the isomerization reaction is reduced, the isomerization time is shortened, the reaction energy consumption is decreased, the cost is reduced, and the optimized catalyst is suitable for industrialized production; (3) the hydrolyzing of diester is effectively reduced, the amount of diacid byproducts is reduced to be 2% or lower, and the product purity is improved; (4) a small amount of unreacted raw material is sent into an organic phase via an extracting procedure, and is separated from the product at high efficiency, so that the purity of the product is further improved.

Ni-Catalyzed Site-Selective Dicarboxylation of 1,3-Dienes with CO2

A site-selective catalytic incorporation of multiple CO2 molecules into 1,3-dienes en route to adipic acids is described. This protocol is characterized by its mild conditions, excellent chemo- and regioselectivity and ease of execution under CO2 (1 atm), including the use of bulk butadiene and/or isoprene feedstocks.

TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR

To provide a novel tricyclic pyrrolopyridine compound having a JAK inhibitory activity and useful for prevention, treatment and/or improvement of particularly autoimmune diseases, inflammatory diseases and allergic diseases. A novel tricyclic pyrrolopyridine compound represented by the formula (I), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof: wherein the respective substituents are defined in detail in the specification, and R1 is a C1-6 alkyl group or the like, R2 is a hydrogen atom or the like, R3 is a hydrogen atom or the like, the ring A is C3-11 cycloalkane or the like, L1 is a C1-6 alkylene group or the like, and R4 is NRaRb or the like.

NITROGENOUS FUSED BICYCLIC COMPOUND

A novel nitrogenous fused bicyclic compound represented by the following general formula [1] or a pharmacologically acceptable salt of the compound. They have excellent SK channel blocking activity and are useful as a medicine. [I] (In the formula, R 0 represents hydrogen, halogeno, etc.; R 1 represents a group represented by the formula (a) or (b); A represents a group represented by the formula (X) or (Y); D 1 , D 2 and D 3 each represents N or CH; R 2 represents halogeno or optionally halogenated lower alkyl, etc.; R 3 represents hydrogen or lower alkyl; and Q represents lower alkylene.)

FUSED FURAN COMPOUND

The present invention provides a condensed furan compound of the formula (I): wherein Ring X is benzene, pyridine, or the like; Y is an optionally substituted amino, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted saturated heterocyclic group, an optionally substituted unsaturated heterocyclic group; A is a single bond, lower alkylene, lower alkenylidene, lower alkenylene or an oxygen atom; R3 is hydrogen or the like; and , R4 is hydrogen, or the like, or pharmaceutically acceptable salts thereof, which is useful as a medicament, particularly, as an activated blood coagulation factor X inhibitor.

Synthesis and mesomorphic properties of trans-[1,4-bis5-R-pyrimidin-2-yl]-cyclohexanes and 1,2-bis-(5-R-pyrimidin-2-yl)ethanes

New trans-bis(5-R-pyrimidin-2-yl)-1,4-cyclohexanes and -1,2-ethanes (R = C7H15, C6H4OR1, where R1 = H, COCH3, C4H9, C5H11, C8/su

Magnetic Field Dependent Reaction Yields from Radical Ion Pairs Linked by a Partially Rigid Aliphatic Chain

The electron donor-acceptor compound pyrene-(CH2)3-cyclohexane-(CH2)3-dimethylaniline, abbreviated as Py3(C6)3DMA, has been investigated.Photoinduced electron transfer leads to the singlet radical ion pair Py-3(C6)3DMA+.An extraordinary large and distinct magnetic field effect is observed in the yield of the locally excited triplet state of the pyrene moiety, the recombination product of the triplet radical ion pair.The half-width of the "J-resonance" maximum in the magnetic field dependent triplet yield curve is just 66 G, corresponding to 7.7*10-7 eV or 6.2*10-3 cm-1.This is due to the influence of the rigid trans-cyclohexane part in the aliphatic chain, which leads to a reduced intramolecular mobility and to a narrow probability distribution of the radical ion pair distance, as predicted by Monte-Carlo computer simulations.The magnetic field dependence of the triplet generation is further transmitted to secondary reactions like triplet-triplet annihilation, thus leading to a magnetic field dependent delayed fluorescence and to a delayed excimer fluorescence.